Literature DB >> 24796664

Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein.

Nobuyuki Yamagishi1, Ryota Nakao2, Rumi Kondo2, Mai Nishitsuji2, Youhei Saito2, Takahisa Kuga2, Takumi Hatayama2, Yuji Nakayama2.   

Abstract

Sorcin, a 22 kDa Ca(2+) binding protein, was first identified in a vincristine-resistant Chinese hamster lung cell line, and was later demonstrated to be involved in the development of multidrug-resistance (MDR) phenotypes in a variety of human cancer cell lines. However, the exact role of sorcin in MDR cells is yet to be fully elucidated. Here we explored the role of sorcin in the development of MDR in leukemia cells, and revealed that the expression level of sorcin was directly correlated to the expression of MDR1/P-glycoprotein (P-gp). In addition, it was shown that sorcin induced the expression of MDR1/P-gp through a cAMP response element (CRE) between -716 and -709 bp of the mdr1/p-gp gene. Furthermore, overexpression of sorcin increased the phosphorylation of CREB1 and the binding of CREB1 to the CRE sequence of mdr1/p-gp promoter, and induced the expression of MDR1/P-gp. These findings suggested that sorcin induces MDR1/P-gp expression markedly through activation of the CREB pathway and is associated with the MDR phenotype. The new findings may be helpful for understanding the mechanisms of MDR in human cancer cells, prompting its further investigation as a molecular target to overcome MDR.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CREB; MDR1/P-glycoprotein; Multidrug-resistance; Sorcin

Mesh:

Substances:

Year:  2014        PMID: 24796664     DOI: 10.1016/j.bbrc.2014.04.125

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.

Authors:  Ping Xu; Yong-Fang Jiang; Jing-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness.

Authors:  Neda Gholamian Dehkordi; Seyed Abbas Mirzaei; Fatemeh Elahian
Journal:  Inflammopharmacology       Date:  2020-10-17       Impact factor: 4.473

3.  Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity.

Authors:  Ziyuan Wang; Long Zhang; Zhenhua Ni; Jian Sun; Hong Gao; Zhuoan Cheng; Jianhua Xu; Peihao Yin
Journal:  Tumour Biol       Date:  2015-07-01

4.  The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.

Authors:  Anita Mangia; Lucia Caldarola; Stefania Dell'Endice; Emanuela Scarpi; Luca Saragoni; Manlio Monti; Daniele Santini; Oronzo Brunetti; Giovanni Simone; Nicola Silvestris
Journal:  Cancer Biol Ther       Date:  2015-06-30       Impact factor: 4.742

Review 5.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

Review 6.  Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance.

Authors:  Ilaria Genovese; Marianna Carinci; Lorenzo Modesti; Gianluca Aguiari; Paolo Pinton; Carlotta Giorgi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

7.  Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous leukemia cell lines.

Authors:  Shi Qinghong; Gao Shen; Song Lina; Zhao Yueming; Li Xiaoou; Wu Jianlin; He Chengyan; Li Hongjun; Zhao Haifeng
Journal:  Proteome Sci       Date:  2015-01-22       Impact factor: 2.480

8.  Optimization Of Cancer Treatment Through Overcoming Drug Resistance.

Authors:  Yahya I Elshimali; Yong Wu; Hussein Khaddour; Yanyuan Wu; Daniela Gradinaru; Hema Sukhija; Seyung S Chung; Jaydutt V Vadgama
Journal:  J Cancer Res Oncobiol       Date:  2018-02-27

Review 9.  Sorcin a Potential Molecular Target for Cancer Therapy.

Authors:  Bano Shabnam; Ganesan Padmavathi; Kishore Banik; Sosmitha Girisa; Javadi Monisha; Gautam Sethi; Lu Fan; Lingzhi Wang; Xinliang Mao; Ajaikumar B Kunnumakkara
Journal:  Transl Oncol       Date:  2018-09-11       Impact factor: 4.243

10.  Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells.

Authors:  Ilaria Genovese; Annarita Fiorillo; Andrea Ilari; Silvia Masciarelli; Francesco Fazi; Gianni Colotti
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.